<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:03:55 -0700</creation_date>
  <update_date>2013-01-15 19:03:55 -0700</update_date>
  <accession>HMDBP02257</accession>
  <secondary_accessions>
    <accession>7742</accession>
  </secondary_accessions>
  <protein_type>Transporter</protein_type>
  <synonyms>
    <synonym>Breast cancer resistance protein</synonym>
    <synonym>CD338 antigen</synonym>
    <synonym>CDw338</synonym>
    <synonym>Mitoxantrone resistance-associated protein</synonym>
    <synonym>Placenta-specific ATP-binding cassette transporter</synonym>
  </synonyms>
  <gene_name>ABCG2</gene_name>
  <general_function>Involved in ATP binding</general_function>
  <specific_function>Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. May be involved in brain-to-blood efflux. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. When overexpressed, the transfected cells become resistant to mitoxantrone, daunorubicin and doxorubicin, display diminished intracellular accumulation of daunorubicin, and manifest an ATP- dependent increase in the efflux of rhodamine 123</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00121</accession>
      <name>Folic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14365</accession>
      <name>Nelfinavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14387</accession>
      <name>Cladribine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14400</accession>
      <name>Diethylstilbestrol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14462</accession>
      <name>Gefitinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14010</accession>
      <name>5-Hydroxyomeprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14542</accession>
      <name>Sorafenib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14587</accession>
      <name>Teniposide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14008</accession>
      <name>Hydroxylansoprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14600</accession>
      <name>Prazosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14613</accession>
      <name>Dronabinol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14646</accession>
      <name>Ritonavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14667</accession>
      <name>Oxaliplatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14671</accession>
      <name>Erlotinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14681</accession>
      <name>Vincristine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14703</accession>
      <name>Methotrexate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14740</accession>
      <name>Ivermectin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13862</accession>
      <name>N-desmethylimatinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00234</accession>
      <name>Testosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14769</accession>
      <name>Clofarabine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13961</accession>
      <name>O-Desmethylverapamil (D-702)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13866</accession>
      <name>N-Desmethyltamoxifen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14832</accession>
      <name>Daunorubicin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14836</accession>
      <name>Nitrofurantoin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14847</accession>
      <name>Lamivudine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14878</accession>
      <name>Riluzole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14879</accession>
      <name>Hydrocortisone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14900</accession>
      <name>Irinotecan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14911</accession>
      <name>Etoposide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00151</accession>
      <name>Estradiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14933</accession>
      <name>Sulfasalazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15101</accession>
      <name>Telmisartan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15105</accession>
      <name>Dactinomycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15132</accession>
      <name>Doxorubicin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15151</accession>
      <name>Glyburide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15164</accession>
      <name>Topotecan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15185</accession>
      <name>Novobiocin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15335</accession>
      <name>Mitoxantrone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15362</accession>
      <name>Saquinavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15364</accession>
      <name>Dexamethasone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15384</accession>
      <name>Dasatinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15397</accession>
      <name>Sunitinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03217</accession>
      <name>Genistein</name>
    </metabolite>
    <metabolite>
      <accession>HMDB33991</accession>
      <name>Daidzin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00036</accession>
      <name>Taurocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00067</accession>
      <name>Cholesterol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15595</accession>
      <name>Nilotinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15672</accession>
      <name>Cabazitaxel</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>nucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, acting on acid anhydrides</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>pyrophosphatase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleoside-triphosphatase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>atpase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleoside binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>purine nucleoside binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adenyl nucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adenyl ribonucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>atp binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:4</chromosome_location>
    <locus>4q22</locus>
    <gene_sequence>&gt;1968 bp
ATGTCTTCCAGTAATGTCGAAGTTTTTATCCCAGTGTCACAAGGAAACACCAATGGCTTC
CCCGCGACAGCTTCCAATGACCTGAAGGCATTTACTGAAGGAGCTGTGTTAAGTTTTCAT
AACATCTGCTATCGAGTAAAACTGAAGAGTGGCTTTCTACCTTGTCGAAAACCAGTTGAG
AAAGAAATATTATCGAATATCAATGGGATCATGAAACCTGGTCTCAACGCCATCCTGGGA
CCCACAGGTGGAGGCAAATCTTCGTTATTAGATGTCTTAGCTGCAAGGAAAGATCCAAGT
GGATTATCTGGAGATGTTCTGATAAATGGAGCACCGCGACCTGCCAATTTCAAATGTAAT
TCAGGTTACGTGGTACAAGATGATGTTGTGATGGGCACTCTGACGGTGAGAGAAAACTTA
CAGTTCTCAGCAGCTCTTCGGCTTGCAACAACTATGACGAATCATGAAAAAAACGAACGG
ATTAACAGGGTCATTCAAGAGTTAGGTCTGGATAAAGTGGCAGACTCCAAGGTTGGAACT
CAGTTTATCCGTGGTGTGTCTGGAGGAGAAAGAAAAAGGACTAGTATAGGAATGGAGCTT
ATCACTGATCCTTCCATCTTGTTCTTGGATGAGCCTACAACTGGCTTAGACTCAAGCACA
GCAAATGCTGTCCTTTTGCTCCTGAAAAGGATGTCTAAGCAGGGACGAACAATCATCTTC
TCCATTCATCAGCCTCGATATTCCATCTTCAAGTTGTTTGATAGCCTCACCTTATTGGCC
TCAGGAAGACTTATGTTCCACGGGCCTGCTCAGGAGGCCTTGGGATACTTTGAATCAGCT
GGTTATCACTGTGAGGCCTATAATAACCCTGCAGACTTCTTCTTGGACATCATTAATGGA
GATTCCACTGCTGTGGCATTAAACAGAGAAGAAGACTTTAAAGCCACAGAGATCATAGAG
CCTTCCAAGCAGGATAAGCCACTCATAGAAAAATTAGCGGAGATTTATGTCAACTCCTCC
TTCTACAAAGAGACAAAAGCTGAATTACATCAACTTTCCGGGGGTGAGAAGAAGAAGAAG
ATCACAGTCTTCAAGGAGATCAGCTACACCACCTCCTTCTGTCATCAACTCAGATGGGTT
TCCAAGCGTTCATTCAAAAACTTGCTGGGTAATCCCCAGGCCTCTATAGCTCAGATCATT
GTCACAGTCGTACTGGGACTGGTTATAGGTGCCATTTACTTTGGGCTAAAAAATGATTCT
ACTGGAATCCAGAACAGAGCTGGGGTTCTCTTCTTCCTGACGACCAACCAGTGTTTCAGC
AGTGTTTCAGCCGTGGAACTCTTTGTGGTAGAGAAGAAGCTCTTCATACATGAATACATC
AGCGGATACTACAGAGTGTCATCTTATTTCCTTGGAAAACTGTTATCTGATTTATTACCC
ATGAGGATGTTACCAAGTATTATATTTACCTGTATAGTGTACTTCATGTTAGGATTGAAG
CCAAAGGCAGATGCCTTCTTCGTTATGATGTTTACCCTTATGATGGTGGCTTATTCAGCC
AGTTCCATGGCACTGGCCATAGCAGCAGGTCAGAGTGTGGTTTCTGTAGCAACACTTCTC
ATGACCATCTGTTTTGTGTTTATGATGATTTTTTCAGGTCTGTTGGTCAATCTCACAACC
ATTGCATCTTGGCTGTCATGGCTTCAGTACTTCAGCATTCCACGATATGGATTTACGGCT
TTGCAGCATAATGAATTTTTGGGACAAAACTTCTGCCCAGGACTCAATGCAACAGGAAAC
AATCCTTGTAACTATGCAACATGTACTGGCGAAGAATATTTGGTAAAGCAGGGCATCGAT
CTCTCACCCTGGGGCTTGTGGAAGAATCACGTGGCCTTGGCTTGTATGATTGTTATTTTC
CTCACAATTGCCTACCTGAAATTGTTATTTCTTAAAAAATATTCTTAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>655</residue_number>
    <molecular_weight>72313.5</molecular_weight>
    <theoretical_pi>8.9</theoretical_pi>
    <pfams>
      <pfam>
        <name>ABC2_membrane</name>
        <pfam_id>PF01061</pfam_id>
      </pfam>
      <pfam>
        <name>ABC_tran</name>
        <pfam_id>PF00005</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>396-416</region>
      <region>429-449</region>
      <region>478-498</region>
      <region>507-527</region>
      <region>536-556</region>
      <region>631-651</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;ATP-binding cassette sub-family G member 2
MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKSGFLPCRKPVE
KEILSNINGIMKPGLNAILGPTGGGKSSLLDVLAARKDPSGLSGDVLINGAPRPANFKCN
SGYVVQDDVVMGTLTVRENLQFSAALRLATTMTNHEKNERINRVIQELGLDKVADSKVGT
QFIRGVSGGERKRTSIGMELITDPSILFLDEPTTGLDSSTANAVLLLLKRMSKQGRTIIF
SIHQPRYSIFKLFDSLTLLASGRLMFHGPAQEALGYFESAGYHCEAYNNPADFFLDIING
DSTAVALNREEDFKATEIIEPSKQDKPLIEKLAEIYVNSSFYKETKAELHQLSGGEKKKK
ITVFKEISYTTSFCHQLRWVSKRSFKNLLGNPQASIAQIIVTVVLGLVIGAIYFGLKNDS
TGIQNRAGVLFFLTTNQCFSSVSAVELFVVEKKLFIHEYISGYYRVSSYFLGKLLSDLLP
MRMLPSIIFTCIVYFMLGLKPKADAFFVMMFTLMMVAYSASSMALAIAAGQSVVSVATLL
MTICFVFMMIFSGLLVNLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQNFCPGLNATGN
NPCNYATCTGEEYLVKQGIDLSPWGLWKNHVALACMIVIFLTIAYLKLLFLKKYS</protein_sequence>
  </protein_properties>
  <genbank_protein_id>13928392</genbank_protein_id>
  <uniprot_id>Q9UNQ0</uniprot_id>
  <uniprot_name>ABCG2_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>AB051855</genbank_gene_id>
  <genecard_id>ABCG2</genecard_id>
  <geneatlas_id>ABCG2</geneatlas_id>
  <hgnc_id>HGNC:74</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M: A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 1998 Dec 1;58(23):5337-9.</reference_text>
      <pubmed_id>9850061</pubmed_id>
    </reference>
    <reference>
      <reference_text>Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells.  Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15665-70.</reference_text>
      <pubmed_id>9861027</pubmed_id>
    </reference>
    <reference>
      <reference_text>Komatani H, Kotani H, Hara Y, Nakagawa R, Matsumoto M, Arakawa H, Nishimura S: Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res. 2001 Apr 1;61(7):2827-32.</reference_text>
      <pubmed_id>11306452</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001 Sep;7(9):1028-34.</reference_text>
      <pubmed_id>11533706</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, Stanimirovic DB: The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J. 2003 Nov;17(14):2085-7. Epub 2003 Sep 4.</reference_text>
      <pubmed_id>12958161</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE: Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 1999 Jan 1;59(1):8-13.</reference_text>
      <pubmed_id>9892175</pubmed_id>
    </reference>
    <reference>
      <reference_text>Schmitz G, Langmann T, Heimerl S: Role of ABCG1 and other ABCG family members in lipid metabolism.  J Lipid Res. 2001 Oct;42(10):1513-20.</reference_text>
      <pubmed_id>11590207</pubmed_id>
    </reference>
    <reference>
      <reference_text>Diop NK, Hrycyna CA: N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. Biochemistry. 2005 Apr 12;44(14):5420-9.</reference_text>
      <pubmed_id>15807535</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ozvegy-Laczka C, Koblos G, Sarkadi B, Varadi A: Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. Biochim Biophys Acta. 2005 Feb 1;1668(1):53-63.</reference_text>
      <pubmed_id>15670731</pubmed_id>
    </reference>
    <reference>
      <reference_text>Henriksen U, Gether U, Litman T: Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2. J Cell Sci. 2005 Apr 1;118(Pt 7):1417-26. Epub 2005 Mar 15.</reference_text>
      <pubmed_id>15769853</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wakabayashi K, Nakagawa H, Tamura A, Koshiba S, Hoshijima K, Komada M, Ishikawa T: Intramolecular disulfide bond is a critical check point determining degradative fates of ATP-binding cassette (ABC) transporter ABCG2 protein. J Biol Chem. 2007 Sep 21;282(38):27841-6. Epub 2007 Aug 8.</reference_text>
      <pubmed_id>17686774</pubmed_id>
    </reference>
    <reference>
      <reference_text>Iida A, Saito S, Sekine A, Mishima C, Kitamura Y, Kondo K, Harigae S, Osawa S, Nakamura Y: Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J Hum Genet. 2002;47(6):285-310.</reference_text>
      <pubmed_id>12111378</pubmed_id>
    </reference>
    <reference>
      <reference_text>Itoda M, Saito Y, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Suzuki H, Sugiyama Y, Ozawa S, Sawada J: Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan. Drug Metab Pharmacokinet. 2003;18(3):212-7.</reference_text>
      <pubmed_id>15618737</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, Schuetz EG: Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics. 2003 Jan;13(1):19-28.</reference_text>
      <pubmed_id>12544509</pubmed_id>
    </reference>
    <reference>
      <reference_text>Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, Bates SE: Single nucleotide polymorphisms modify the transporter activity of ABCG2.  Cancer Chemother Pharmacol. 2005 Aug;56(2):161-72. Epub 2005 Apr 19.</reference_text>
      <pubmed_id>15838659</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Folic acid</name>
        <accession>HMDB00121</accession>
      </metabolite>
      <reference>
        <reference_text>Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD: Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54.</reference_text>
        <pubmed_id>12874005</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nelfinavir</name>
        <accession>HMDB14365</accession>
      </metabolite>
      <reference>
        <reference_text>Gupta A, Zhang Y, Unadkat JD, Mao Q: HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2004 Jul;310(1):334-41. Epub 2004 Mar 8.</reference_text>
        <pubmed_id>15007102</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cladribine</name>
        <accession>HMDB14387</accession>
      </metabolite>
      <reference>
        <reference_text>de Wolf C, Jansen R, Yamaguchi H, de Haas M, van de Wetering K, Wijnholds J, Beijnen J, Borst P: Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102. Epub 2008 Sep 2.</reference_text>
        <pubmed_id>18765824</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylstilbestrol</name>
        <accession>HMDB14400</accession>
      </metabolite>
      <reference>
        <reference_text>Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T: Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther. 2003 Jan;2(1):105-12.</reference_text>
        <pubmed_id>12533678</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gefitinib</name>
        <accession>HMDB14462</accession>
      </metabolite>
      <reference>
        <reference_text>Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B: High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol. 2004 Jun;65(6):1485-95.</reference_text>
        <pubmed_id>15155841</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gefitinib</name>
        <accession>HMDB14462</accession>
      </metabolite>
      <reference>
        <reference_text>An Y, Ongkeko WM: ABCG2: the key to chemoresistance in cancer stem cells?  Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1529-42.</reference_text>
        <pubmed_id>19708828</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gefitinib</name>
        <accession>HMDB14462</accession>
      </metabolite>
      <reference>
        <reference_text>Shen J, Carcaboso AM, Hubbard KE, Tagen M, Wynn HG, Panetta JC, Waters CM, Elmeliegy MA, Stewart CF: Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Res. 2009 Jul 15;69(14):5885-92. Epub 2009 Jun 30.</reference_text>
        <pubmed_id>19567673</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gefitinib</name>
        <accession>HMDB14462</accession>
      </metabolite>
      <reference>
        <reference_text>Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. Epub 2009 May 12.</reference_text>
        <pubmed_id>19493273</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gefitinib</name>
        <accession>HMDB14462</accession>
      </metabolite>
      <reference>
        <reference_text>Shi Z, Parmar S, Peng XX, Shen T, Robey RW, Bates SE, Fu LW, Shao Y, Chen YM, Zang F, Chen ZS: The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncol Rep. 2009 Feb;21(2):483-9.</reference_text>
        <pubmed_id>19148526</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-Hydroxyomeprazole</name>
        <accession>HMDB14010</accession>
      </metabolite>
      <reference>
        <reference_text>Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11.</reference_text>
        <pubmed_id>15313923</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-Hydroxyomeprazole</name>
        <accession>HMDB14010</accession>
      </metabolite>
      <reference>
        <reference_text>Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. Epub 2008 Nov 17.</reference_text>
        <pubmed_id>19076159</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sorafenib</name>
        <accession>HMDB14542</accession>
      </metabolite>
      <reference>
        <reference_text>Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. Epub 2009 Sep 22.</reference_text>
        <pubmed_id>19773380</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sorafenib</name>
        <accession>HMDB14542</accession>
      </metabolite>
      <reference>
        <reference_text>Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH: Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010 Feb;9(2):319-26. Epub 2010 Jan 26.</reference_text>
        <pubmed_id>20103600</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Teniposide</name>
        <accession>HMDB14587</accession>
      </metabolite>
      <reference>
        <reference_text>Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH: Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003 Mar 15;63(6):1339-44.</reference_text>
        <pubmed_id>12649196</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxylansoprazole</name>
        <accession>HMDB14008</accession>
      </metabolite>
      <reference>
        <reference_text>Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. Epub 2008 Nov 17.</reference_text>
        <pubmed_id>19076159</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. Epub 2010 Apr 27.</reference_text>
        <pubmed_id>20423956</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B: Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.</reference_text>
        <pubmed_id>11437380</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dronabinol</name>
        <accession>HMDB14613</accession>
      </metabolite>
      <reference>
        <reference_text>Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X: Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010 Aug;13(7):905-15. Epub 2009 Nov 4.</reference_text>
        <pubmed_id>19887017</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ritonavir</name>
        <accession>HMDB14646</accession>
      </metabolite>
      <reference>
        <reference_text>Gupta A, Zhang Y, Unadkat JD, Mao Q: HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2004 Jul;310(1):334-41. Epub 2004 Mar 8.</reference_text>
        <pubmed_id>15007102</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxaliplatin</name>
        <accession>HMDB14667</accession>
      </metabolite>
      <reference>
        <reference_text>Ceckova M, Vackova Z, Radilova H, Libra A, Buncek M, Staud F: Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP.  Toxicol In Vitro. 2008 Dec;22(8):1846-52. Epub 2008 Sep 9.</reference_text>
        <pubmed_id>18801423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erlotinib</name>
        <accession>HMDB14671</accession>
      </metabolite>
      <reference>
        <reference_text>Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. Epub 2009 May 12.</reference_text>
        <pubmed_id>19493273</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH: Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003 Mar 15;63(6):1339-44.</reference_text>
        <pubmed_id>12649196</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics.  J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7.</reference_text>
        <pubmed_id>12682043</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11.</reference_text>
        <pubmed_id>15313923</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Mitomo H, Kato R, Ito A, Kasamatsu S, Ikegami Y, Kii I, Kudo A, Kobatake E, Sumino Y, Ishikawa T: A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem J. 2003 Aug 1;373(Pt 3):767-74.</reference_text>
        <pubmed_id>12741957</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD: Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54.</reference_text>
        <pubmed_id>12874005</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Volk EL, Schneider E: Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.</reference_text>
        <pubmed_id>14500392</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. Epub 2008 Nov 17.</reference_text>
        <pubmed_id>19076159</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Hou YX, Li CZ, Palaniyandi K, Magtibay PM, Homolya L, Sarkadi B, Chang XB: Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport. Biochemistry. 2009 Sep 29;48(38):9122-31.</reference_text>
        <pubmed_id>19691360</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. Epub 2009 Apr 11.</reference_text>
        <pubmed_id>19427995</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW: Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 2009 Jun 28;279(1):74-83. Epub 2009 Feb 18.</reference_text>
        <pubmed_id>19232821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ivermectin</name>
        <accession>HMDB14740</accession>
      </metabolite>
      <reference>
        <reference_text>Jani M, Makai I, Kis E, Szabo P, Nagy T, Krajcsi P, Lespine A: Ivermectin interacts with human ABCG2.  J Pharm Sci. 2011 Jan;100(1):94-7. doi: 10.1002/jps.22262. Epub 2010 Jun 22.</reference_text>
        <pubmed_id>20574995</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P: Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 2004 Apr 1;64(7):2333-7.</reference_text>
        <pubmed_id>15059881</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>An Y, Ongkeko WM: ABCG2: the key to chemoresistance in cancer stem cells?  Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1529-42.</reference_text>
        <pubmed_id>19708828</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ, Jorgensen HG, Holyoake TL, Pirmohamed M, Clark RE, Mountford JC: Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia. 2009 Nov;23(11):1999-2006. Epub 2009 Aug 27.</reference_text>
        <pubmed_id>19710702</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. Epub 2010 Apr 27.</reference_text>
        <pubmed_id>20423956</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K: Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2. Epub 2004 Jul 13.</reference_text>
        <pubmed_id>15251980</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. Epub 2009 Sep 28.</reference_text>
        <pubmed_id>19785662</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH: The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 2005 Apr 1;65(7):2577-82.</reference_text>
        <pubmed_id>15805252</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Oka M, Fukuda M, Soda H: [Anticancer drugs and ABC transporters].  Gan To Kagaku Ryoho. 2005 May;32(5):585-92.</reference_text>
        <pubmed_id>15918555</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K: Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52. Epub 2005 Jul 9.</reference_text>
        <pubmed_id>15970668</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Yanase K, Tsukahara S, Mitsuhashi J, Sugimoto Y: Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development. Cancer Lett. 2006 Mar 8;234(1):73-80. Epub 2005 Nov 21.</reference_text>
        <pubmed_id>16303243</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Nakanishi T, Shiozawa K, Hassel BA, Ross DD: Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood. 2006 Jul 15;108(2):678-84. Epub 2006 Mar 16.</reference_text>
        <pubmed_id>16543472</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Testosterone</name>
        <accession>HMDB00234</accession>
      </metabolite>
      <reference>
        <reference_text>Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, van Veen HW: Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51. Epub 2003 Mar 28.</reference_text>
        <pubmed_id>12668685</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clofarabine</name>
        <accession>HMDB14769</accession>
      </metabolite>
      <reference>
        <reference_text>de Wolf C, Jansen R, Yamaguchi H, de Haas M, van de Wetering K, Wijnholds J, Beijnen J, Borst P: Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102. Epub 2008 Sep 2.</reference_text>
        <pubmed_id>18765824</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B: High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol. 2004 Jun;65(6):1485-95.</reference_text>
        <pubmed_id>15155841</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, van Veen HW: Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51. Epub 2003 Mar 28.</reference_text>
        <pubmed_id>12668685</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, van Veen HW: Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51. Epub 2003 Mar 28.</reference_text>
        <pubmed_id>12668685</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B: Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.</reference_text>
        <pubmed_id>11437380</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S, Pumplin DW, Fang HB, Ross DD: Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. Mol Pharmacol. 2003 Dec;64(6):1452-62.</reference_text>
        <pubmed_id>14645676</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrofurantoin</name>
        <accession>HMDB14836</accession>
      </metabolite>
      <reference>
        <reference_text>Perez M, Real R, Mendoza G, Merino G, Prieto JG, Alvarez AI: Milk secretion of nitrofurantoin, as a specific BCRP/ABCG2 substrate, in assaf sheep: modulation by isoflavones. J Vet Pharmacol Ther. 2009 Oct;32(5):498-502.</reference_text>
        <pubmed_id>19754918</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lamivudine</name>
        <accession>HMDB14847</accession>
      </metabolite>
      <reference>
        <reference_text>Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M: Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72.</reference_text>
        <pubmed_id>12488537</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Riluzole</name>
        <accession>HMDB14878</accession>
      </metabolite>
      <reference>
        <reference_text>Milane A, Vautier S, Chacun H, Meininger V, Bensimon G, Farinotti R, Fernandez C: Interactions between riluzole and ABCG2/BCRP transporter.  Neurosci Lett. 2009 Mar 6;452(1):12-6. Epub 2009 Jan 6.</reference_text>
        <pubmed_id>19146924</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocortisone</name>
        <accession>HMDB14879</accession>
      </metabolite>
      <reference>
        <reference_text>Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003 Sep;64(3):610-8.</reference_text>
        <pubmed_id>12920197</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Irinotecan</name>
        <accession>HMDB14900</accession>
      </metabolite>
      <reference>
        <reference_text>Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M: Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72.</reference_text>
        <pubmed_id>12488537</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Irinotecan</name>
        <accession>HMDB14900</accession>
      </metabolite>
      <reference>
        <reference_text>Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, van Waardenburg RC, de Jong LA, Pluim D, Beijnen JH, Schellens JH: Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res. 2001 Apr;7(4):935-41.</reference_text>
        <pubmed_id>11309344</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etoposide</name>
        <accession>HMDB14911</accession>
      </metabolite>
      <reference>
        <reference_text>Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M: Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72.</reference_text>
        <pubmed_id>12488537</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etoposide</name>
        <accession>HMDB14911</accession>
      </metabolite>
      <reference>
        <reference_text>Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH: Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003 Mar 15;63(6):1339-44.</reference_text>
        <pubmed_id>12649196</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estradiol</name>
        <accession>HMDB00151</accession>
      </metabolite>
      <reference>
        <reference_text>Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003 Sep;64(3):610-8.</reference_text>
        <pubmed_id>12920197</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estradiol</name>
        <accession>HMDB00151</accession>
      </metabolite>
      <reference>
        <reference_text>Imai Y, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res. 2002 Mar;93(3):231-5.</reference_text>
        <pubmed_id>11927002</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfasalazine</name>
        <accession>HMDB14933</accession>
      </metabolite>
      <reference>
        <reference_text>Karlsson JE, Heddle C, Rozkov A, Rotticci-Mulder J, Tuvesson O, Hilgendorf C, Andersson TB: High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells. Drug Metab Dispos. 2010 Apr;38(4):705-14. Epub 2010 Jan 13.</reference_text>
        <pubmed_id>20071452</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfasalazine</name>
        <accession>HMDB14933</accession>
      </metabolite>
      <reference>
        <reference_text>Shukla S, Zaher H, Hartz A, Bauer B, Ware JA, Ambudkar SV: Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7. Epub 2008 Oct 9.</reference_text>
        <pubmed_id>18841445</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfasalazine</name>
        <accession>HMDB14933</accession>
      </metabolite>
      <reference>
        <reference_text>Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. Epub 2009 Jun       18.</reference_text>
        <pubmed_id>19541926</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Telmisartan</name>
        <accession>HMDB15101</accession>
      </metabolite>
      <reference>
        <reference_text>Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61.</reference_text>
        <pubmed_id>20222053</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dactinomycin</name>
        <accession>HMDB15105</accession>
      </metabolite>
      <reference>
        <reference_text>Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M: Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72.</reference_text>
        <pubmed_id>12488537</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics.  J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7.</reference_text>
        <pubmed_id>12682043</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M: Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72.</reference_text>
        <pubmed_id>12488537</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B: Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.</reference_text>
        <pubmed_id>11437380</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH: Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003 Mar 15;63(6):1339-44.</reference_text>
        <pubmed_id>12649196</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>An Y, Ongkeko WM: ABCG2: the key to chemoresistance in cancer stem cells?  Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1529-42.</reference_text>
        <pubmed_id>19708828</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. Epub 2009 Apr 11.</reference_text>
        <pubmed_id>19427995</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW: Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 2009 Jun 28;279(1):74-83. Epub 2009 Feb 18.</reference_text>
        <pubmed_id>19232821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Zheng LS, Wang F, Li YH, Zhang X, Chen LM, Liang YJ, Dai CL, Yan YY, Tao LY, Mi YJ, Yang AK, To KK, Fu LW: Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One. 2009;4(4):e5172. Epub 2009 Apr 23.</reference_text>
        <pubmed_id>19390592</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glyburide</name>
        <accession>HMDB15151</accession>
      </metabolite>
      <reference>
        <reference_text>Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. Epub 2006 Feb 3.</reference_text>
        <pubmed_id>16460798</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glyburide</name>
        <accession>HMDB15151</accession>
      </metabolite>
      <reference>
        <reference_text>Pollex EK, Anger G, Hutson J, Koren G, Piquette-Miller M: Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism. Drug Metab Dispos. 2010 May;38(5):740-4. Epub 2010 Feb 16.</reference_text>
        <pubmed_id>20159988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Topotecan</name>
        <accession>HMDB15164</accession>
      </metabolite>
      <reference>
        <reference_text>Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P: Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 2004 Apr 1;64(7):2333-7.</reference_text>
        <pubmed_id>15059881</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Topotecan</name>
        <accession>HMDB15164</accession>
      </metabolite>
      <reference>
        <reference_text>Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, van Waardenburg RC, de Jong LA, Pluim D, Beijnen JH, Schellens JH: Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res. 2001 Apr;7(4):935-41.</reference_text>
        <pubmed_id>11309344</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Topotecan</name>
        <accession>HMDB15164</accession>
      </metabolite>
      <reference>
        <reference_text>Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T: Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther. 2003 Jan;2(1):105-12.</reference_text>
        <pubmed_id>12533678</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Topotecan</name>
        <accession>HMDB15164</accession>
      </metabolite>
      <reference>
        <reference_text>Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 1999 Sep 15;59(18):4559-63.</reference_text>
        <pubmed_id>10493507</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Topotecan</name>
        <accession>HMDB15164</accession>
      </metabolite>
      <reference>
        <reference_text>Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH: Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst. 2000 Oct 18;92(20):1651-6.</reference_text>
        <pubmed_id>11036110</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Topotecan</name>
        <accession>HMDB15164</accession>
      </metabolite>
      <reference>
        <reference_text>Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH: Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003 Mar 15;63(6):1339-44.</reference_text>
        <pubmed_id>12649196</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Topotecan</name>
        <accession>HMDB15164</accession>
      </metabolite>
      <reference>
        <reference_text>Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11.</reference_text>
        <pubmed_id>15313923</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Topotecan</name>
        <accession>HMDB15164</accession>
      </metabolite>
      <reference>
        <reference_text>Carcaboso AM, Elmeliegy MA, Shen J, Juel SJ, Zhang ZM, Calabrese C, Tracey L, Waters CM, Stewart CF: Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.  Cancer Res. 2010 Jun 1;70(11):4499-508. Epub 2010 May 11.</reference_text>
        <pubmed_id>20460504</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Topotecan</name>
        <accession>HMDB15164</accession>
      </metabolite>
      <reference>
        <reference_text>Shen J, Carcaboso AM, Hubbard KE, Tagen M, Wynn HG, Panetta JC, Waters CM, Elmeliegy MA, Stewart CF: Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Res. 2009 Jul 15;69(14):5885-92. Epub 2009 Jun 30.</reference_text>
        <pubmed_id>19567673</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Topotecan</name>
        <accession>HMDB15164</accession>
      </metabolite>
      <reference>
        <reference_text>Rocchi E, Khodjakov A, Volk EL, Yang CH, Litman T, Bates SE, Schneider E: The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem Biophys Res Commun. 2000 Apr 29;271(1):42-6.</reference_text>
        <pubmed_id>10777678</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Topotecan</name>
        <accession>HMDB15164</accession>
      </metabolite>
      <reference>
        <reference_text>Ishii M, Iwahana M, Mitsui I, Minami M, Imagawa S, Tohgo A, Ejima A: Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. Anticancer Drugs. 2000 Jun;11(5):353-62.</reference_text>
        <pubmed_id>10912951</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Topotecan</name>
        <accession>HMDB15164</accession>
      </metabolite>
      <reference>
        <reference_text>Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E, Chen YC: BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.  Biochem Pharmacol. 2000 Sep 15;60(6):831-7.</reference_text>
        <pubmed_id>10930538</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Novobiocin</name>
        <accession>HMDB15185</accession>
      </metabolite>
      <reference>
        <reference_text>Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. Epub 2006 Feb 3.</reference_text>
        <pubmed_id>16460798</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Novobiocin</name>
        <accession>HMDB15185</accession>
      </metabolite>
      <reference>
        <reference_text>Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S: Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer. 2004 Jan 1;108(1):146-51.</reference_text>
        <pubmed_id>14618629</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Novobiocin</name>
        <accession>HMDB15185</accession>
      </metabolite>
      <reference>
        <reference_text>Elahian F, Kalalinia F, Behravan J: Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem Toxicol. 2010 Apr;33(2):113-9.</reference_text>
        <pubmed_id>20307139</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Volk EL, Schneider E: Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.</reference_text>
        <pubmed_id>14500392</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Elahian F, Kalalinia F, Behravan J: Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem Toxicol. 2010 Apr;33(2):113-9.</reference_text>
        <pubmed_id>20307139</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Morrow CS, Peklak-Scott C, Bishwokarma B, Kute TE, Smitherman PK, Townsend AJ: Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol. 2006 Apr;69(4):1499-505. Epub 2006 Jan 24.</reference_text>
        <pubmed_id>16434618</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, Bates SE: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci. 2000 Jun;113 ( Pt 11):2011-21.</reference_text>
        <pubmed_id>10806112</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M: Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72.</reference_text>
        <pubmed_id>12488537</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T: Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther. 2003 Jan;2(1):105-12.</reference_text>
        <pubmed_id>12533678</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 1999 Sep 15;59(18):4559-63.</reference_text>
        <pubmed_id>10493507</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B: Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.</reference_text>
        <pubmed_id>11437380</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003 Sep;64(3):610-8.</reference_text>
        <pubmed_id>12920197</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Miwa M, Tsukahara S, Ishikawa E, Asada S, Imai Y, Sugimoto Y: Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants. Int J Cancer. 2003 Dec 10;107(5):757-63.</reference_text>
        <pubmed_id>14566825</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S, Pumplin DW, Fang HB, Ross DD: Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. Mol Pharmacol. 2003 Dec;64(6):1452-62.</reference_text>
        <pubmed_id>14645676</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH: Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003 Mar 15;63(6):1339-44.</reference_text>
        <pubmed_id>12649196</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH: The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 1999 Sep 1;59(17):4237-41.</reference_text>
        <pubmed_id>10485464</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>An Y, Ongkeko WM: ABCG2: the key to chemoresistance in cancer stem cells?  Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1529-42.</reference_text>
        <pubmed_id>19708828</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Paturi DK, Kwatra D, Ananthula HK, Pal D, Mitra AK: Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3). Int J Pharm. 2010 Jan 15;384(1-2):32-8. Epub 2009 Sep 25.</reference_text>
        <pubmed_id>19782742</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Ma Y, Wink M: The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res. 2010 Jan;24(1):146-9.</reference_text>
        <pubmed_id>19548284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Mahringer A, Delzer J, Fricker G: A fluorescence-based in vitro assay for drug interactions with breast cancer resistance protein (BCRP, ABCG2). Eur J Pharm Biopharm. 2009 Aug;72(3):605-13.</reference_text>
        <pubmed_id>19572416</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Nicolle E, Boccard J, Guilet D, Dijoux-Franca MG, Zelefac F, Macalou S, Grosselin J, Schmidt J, Carrupt PA, Di Pietro A, Boumendjel A: Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach. Eur J Pharm Sci. 2009 Aug 12;38(1):39-46. Epub 2009 Jun 6.</reference_text>
        <pubmed_id>19501160</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Jani M, Szabo P, Kis E, Molnar E, Glavinas H, Krajcsi P: Kinetic characterization of sulfasalazine transport by human ATP-binding cassette G2. Biol Pharm Bull. 2009 Mar;32(3):497-9.</reference_text>
        <pubmed_id>19252303</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Karla PK, Earla R, Boddu SH, Johnston TP, Pal D, Mitra A: Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells. Curr Eye Res. 2009 Jan;34(1):1-9.</reference_text>
        <pubmed_id>19172464</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. Epub 2009 Apr 11.</reference_text>
        <pubmed_id>19427995</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. Epub 2009 May 12.</reference_text>
        <pubmed_id>19493273</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Shi Z, Parmar S, Peng XX, Shen T, Robey RW, Bates SE, Fu LW, Shao Y, Chen YM, Zang F, Chen ZS: The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncol Rep. 2009 Feb;21(2):483-9.</reference_text>
        <pubmed_id>19148526</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, Doyle LA: Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst. 1999 Mar 3;91(5):429-33.</reference_text>
        <pubmed_id>10070941</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, Robey R, Pommier Y, Fojo T, Bates SE: Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 1999 Dec 1;59(23):5938-46.</reference_text>
        <pubmed_id>10606239</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Rocchi E, Khodjakov A, Volk EL, Yang CH, Litman T, Bates SE, Schneider E: The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem Biophys Res Commun. 2000 Apr 29;271(1):42-6.</reference_text>
        <pubmed_id>10777678</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH: Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst. 2000 Oct 18;92(20):1651-6.</reference_text>
        <pubmed_id>11036110</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saquinavir</name>
        <accession>HMDB15362</accession>
      </metabolite>
      <reference>
        <reference_text>Gupta A, Zhang Y, Unadkat JD, Mao Q: HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2004 Jul;310(1):334-41. Epub 2004 Mar 8.</reference_text>
        <pubmed_id>15007102</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saquinavir</name>
        <accession>HMDB15362</accession>
      </metabolite>
      <reference>
        <reference_text>Janneh O, Owen A, Chandler B, Hartkoorn RC, Hart CA, Bray PG, Ward SA, Back DJ, Khoo SH: Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS. 2005 Dec 2;19(18):2097-102.</reference_text>
        <pubmed_id>16284458</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexamethasone</name>
        <accession>HMDB15364</accession>
      </metabolite>
      <reference>
        <reference_text>Elahian F, Kalalinia F, Behravan J: Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem Toxicol. 2010 Apr;33(2):113-9.</reference_text>
        <pubmed_id>20307139</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dasatinib</name>
        <accession>HMDB15384</accession>
      </metabolite>
      <reference>
        <reference_text>Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. Epub 2010 Apr 27.</reference_text>
        <pubmed_id>20423956</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dasatinib</name>
        <accession>HMDB15384</accession>
      </metabolite>
      <reference>
        <reference_text>Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. Epub 2009 Sep 28.</reference_text>
        <pubmed_id>19785662</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sunitinib</name>
        <accession>HMDB15397</accession>
      </metabolite>
      <reference>
        <reference_text>Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. Epub 2009 Sep 22.</reference_text>
        <pubmed_id>19773380</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sunitinib</name>
        <accession>HMDB15397</accession>
      </metabolite>
      <reference>
        <reference_text>Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW: Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 2009 Jun 28;279(1):74-83. Epub 2009 Feb 18.</reference_text>
        <pubmed_id>19232821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sunitinib</name>
        <accession>HMDB15397</accession>
      </metabolite>
      <reference>
        <reference_text>Shukla S, Robey RW, Bates SE, Ambudkar SV: Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009 Feb;37(2):359-65. Epub 2008 Oct 29.</reference_text>
        <pubmed_id>18971320</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Genistein</name>
        <accession>HMDB03217</accession>
      </metabolite>
      <reference>
        <reference_text>Imai Y, Tsukahara S, Asada S, Sugimoto Y: Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res. 2004 Jun 15;64(12):4346-52.</reference_text>
        <pubmed_id>15205350</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Genistein</name>
        <accession>HMDB03217</accession>
      </metabolite>
      <reference>
        <reference_text>Zhang S, Yang X, Morris ME: Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol. 2004 May;65(5):1208-16.</reference_text>
        <pubmed_id>15102949</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Genistein</name>
        <accession>HMDB03217</accession>
      </metabolite>
      <reference>
        <reference_text>Perez M, Real R, Mendoza G, Merino G, Prieto JG, Alvarez AI: Milk secretion of nitrofurantoin, as a specific BCRP/ABCG2 substrate, in assaf sheep: modulation by isoflavones. J Vet Pharmacol Ther. 2009 Oct;32(5):498-502.</reference_text>
        <pubmed_id>19754918</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daidzin</name>
        <accession>HMDB33991</accession>
      </metabolite>
      <reference>
        <reference_text>Perez M, Real R, Mendoza G, Merino G, Prieto JG, Alvarez AI: Milk secretion of nitrofurantoin, as a specific BCRP/ABCG2 substrate, in assaf sheep: modulation by isoflavones. J Vet Pharmacol Ther. 2009 Oct;32(5):498-502.</reference_text>
        <pubmed_id>19754918</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003 Sep;64(3):610-8.</reference_text>
        <pubmed_id>12920197</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cholesterol</name>
        <accession>HMDB00067</accession>
      </metabolite>
      <reference>
        <reference_text>Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, van Veen HW: Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51. Epub 2003 Mar 28.</reference_text>
        <pubmed_id>12668685</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nilotinib</name>
        <accession>HMDB15595</accession>
      </metabolite>
      <reference>
        <reference_text>Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. Epub 2009 Apr 11.</reference_text>
        <pubmed_id>19427995</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nilotinib</name>
        <accession>HMDB15595</accession>
      </metabolite>
      <reference>
        <reference_text>Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. Epub 2009 Sep 28.</reference_text>
        <pubmed_id>19785662</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nilotinib</name>
        <accession>HMDB15595</accession>
      </metabolite>
      <reference>
        <reference_text>Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. Epub 2010 Sep 1.</reference_text>
        <pubmed_id>20810928</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
